Role of the microenvironment for radiosensitization by patupilone

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1335-1342

  Bley, Carla Rohrer ^a,b   Jochum, Wolfram ^a   Orlowski, Katrin ^a   Furmanova, Polina ^a   Vuong, Van ^a   McSheehy, Paul M J ^c   Pruschy, Martin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; MICROVASCULATURE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RADIOSENSITIZATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CELL HYPOXIA; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; EPOTHILONES; HUMANS; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 63149182838     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0969     Document Type: Article

References (25)

1. Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new mi- crotubule-stabilizing agents. Nat Prod Rep 2007;24: 327-57.
2. Altmann KH.Wartmann M, O'ReillyT. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000;1470:M79-91.
3. He L, Yang CP, Horwitz SB. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001;1:3-10.
4. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 2000;69:277-302.
5. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anticancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-54.
6. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 1995;55: 2325-33.
7. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
8. Ferretti S, Allegrini PR, O'ReillyT, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11: 7773-84.
9. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
10. Thorpe PE. vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
11. Escuin D, Kline ER, Giannakakou P. Both microtu- bule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function. Cancer Res 2005:65:9021 -8.
12. Pasquier E, Honore S, Braguer D. Microtubule- targeting agents in angiogenesis: where do we stand? Drug Resist Updat 2006;9:74 -86.
13. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928-42.
14. Sinclair WK. Cyclic X-ray responses in mammalian cells in vitro. Radiat Res 1968;33:620-43.
15. Hofstetter B,Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug- resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005;11:1588-96.
16. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA2000;97:2904-9.
17. Wang Y, O'Brate A, Zhou W, Giannakakou P. Resistance to microtubule-stabilizing drugs involves two events: β-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 2005;4:1847-53.
18. Yang CP, Verdier-Pinard P, Wang F, et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 2005;4:987-95.
19. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogene- sis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
20. Pasquier E, Carre M, Pourroy B, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004:3:1301 -10.
21. Oehler-Janne C, Jochum W, Riesterer O, et al. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther 2007;6:2496 - 504.
22. Riesterer O, Honer M, Jochum W, Oehler C, Ametamey S, Pruschy M. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 2006;12:3518-24.
23. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
24. Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004;14:215-21.
25. Rak J, Yu JL. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". Semin Cancer Biol 2004;14:93-104.